Market Closed -
Nasdaq Stockholm
12:00:00 2024-06-26 EDT
|
5-day change
|
1st Jan Change
|
3.18
SEK
|
-2.45%
|
|
+0.63%
|
-49.76%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
781.4
|
2,648
|
2,669
|
1,313
|
479.4
|
240.8
|
-
|
-
|
Enterprise Value (EV)
1 |
729.3
|
2,485
|
2,553
|
1,267
|
391.2
|
120.8
|
165.8
|
196.8
|
P/E ratio
|
-25.4
x
|
-97.8
x
|
-90.2
x
|
-20.3
x
|
-3.75
x
|
-3.46
x
|
-3.98
x
|
-5.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
64.4
x
|
554
x
|
509
x
|
136
x
|
59.8
x
|
12.4
x
|
4.54
x
|
2.08
x
|
EV / Revenue
|
60.1
x
|
520
x
|
487
x
|
131
x
|
48.8
x
|
6.2
x
|
3.12
x
|
1.7
x
|
EV / EBITDA
|
-33.6
x
|
-127
x
|
-110
x
|
-29.1
x
|
-5.67
x
|
-2.46
x
|
-4.68
x
|
-12.9
x
|
EV / FCF
|
-17.5
x
|
-78.9
x
|
-53.3
x
|
-16.7
x
|
-8.16
x
|
-2.01
x
|
-3.53
x
|
-6.15
x
|
FCF Yield
|
-5.72%
|
-1.27%
|
-1.88%
|
-5.99%
|
-12.3%
|
-49.7%
|
-28.3%
|
-16.3%
|
Price to Book
|
3.55
x
|
7.84
x
|
8.66
x
|
5.25
x
|
2.01
x
|
0.92
x
|
1.15
x
|
1.37
x
|
Nbr of stocks (in thousands)
|
43,293
|
50,160
|
50,160
|
50,491
|
75,736
|
75,736
|
-
|
-
|
Reference price
2 |
18.05
|
52.80
|
53.20
|
26.00
|
6.330
|
3.180
|
3.180
|
3.180
|
Announcement Date
|
20-02-21
|
21-02-18
|
22-02-18
|
23-02-17
|
24-02-16
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12.14
|
4.78
|
5.241
|
9.684
|
8.015
|
19.5
|
53.1
|
115.7
|
EBITDA
1 |
-21.69
|
-19.5
|
-23.24
|
-43.56
|
-68.98
|
-49.1
|
-35.4
|
-15.3
|
EBIT
1 |
-27.85
|
-25.68
|
-29.39
|
-64.41
|
-93.58
|
-71.6
|
-62
|
-43.2
|
Operating Margin
|
-229.41%
|
-537.15%
|
-560.83%
|
-665.15%
|
-1,167.55%
|
-367.18%
|
-116.76%
|
-37.34%
|
Earnings before Tax (EBT)
1 |
-27.89
|
-25.6
|
-29.38
|
-64.16
|
-91.46
|
-70
|
-60
|
-42
|
Net income
1 |
-27.89
|
-25.6
|
-29.38
|
-64.16
|
-102.9
|
-70
|
-60
|
-44
|
Net margin
|
-229.77%
|
-535.59%
|
-560.48%
|
-662.52%
|
-1,283.24%
|
-358.97%
|
-112.99%
|
-38.03%
|
EPS
2 |
-0.7100
|
-0.5400
|
-0.5900
|
-1.280
|
-1.690
|
-0.9200
|
-0.8000
|
-0.5800
|
Free Cash Flow
1 |
-41.73
|
-31.5
|
-47.9
|
-75.92
|
-47.94
|
-60
|
-47
|
-32
|
FCF margin
|
-343.78%
|
-658.97%
|
-913.95%
|
-783.99%
|
-598.14%
|
-307.69%
|
-88.51%
|
-27.66%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-21
|
21-02-18
|
22-02-18
|
23-02-17
|
24-02-16
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
2.18
|
-
|
2.612
|
2.016
|
EBITDA
1 |
-
|
-
|
-9.805
|
-8.612
|
EBIT
1 |
-8.798
|
-
|
-15.74
|
-14.58
|
Operating Margin
|
-403.58%
|
-
|
-602.57%
|
-723.36%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-15.77
|
-14.62
|
Net income
1 |
-8.729
|
-10.73
|
-15.77
|
-14.62
|
Net margin
|
-400.41%
|
-
|
-603.71%
|
-724.95%
|
EPS
|
-0.1700
|
-0.2100
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-02-18
|
22-05-20
|
22-08-31
|
22-11-10
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
52.1
|
164
|
115
|
45.5
|
88.2
|
120
|
75
|
44
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-41.7
|
-31.5
|
-47.9
|
-75.9
|
-47.9
|
-60
|
-47
|
-32
|
ROE (net income / shareholders' equity)
|
-13.6%
|
-9.19%
|
-9.1%
|
-23%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.080
|
6.730
|
6.150
|
4.950
|
3.140
|
3.460
|
2.770
|
2.320
|
Cash Flow per Share
|
-
|
-0.4300
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
39.1
|
11.4
|
22.4
|
5.25
|
0.06
|
-
|
1
|
1
|
Capex / Sales
|
322%
|
238.87%
|
428.11%
|
54.22%
|
0.7%
|
-
|
1.88%
|
0.86%
|
Announcement Date
|
20-02-21
|
21-02-18
|
22-02-18
|
23-02-17
|
24-02-16
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -49.76% | 23.47M | | +16.49% | 122B | | +21.73% | 116B | | +22.18% | 27.03B | | -21.81% | 20.36B | | -16.89% | 16.43B | | -18.81% | 15.91B | | -44.74% | 15.6B | | +62.72% | 14.94B | | +3.09% | 13.59B |
Bio Therapeutic Drugs
|